Hospital Palliative Care Team Consultations in Different Subgroups of Hematologic Malignancies [0.03%]
血液系统恶性肿瘤不同亚组的医院姑息治疗团队会诊
Anja M Caspers,Anne Pralong,Michael Hallek et al.
Anja M Caspers et al.
In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms [0.03%]
TCRβ亚型原位跟踪检测T细胞克隆性及其在T细胞肿瘤的精准诊断和靶向免疫治疗中的应用价值研究
Marie Therese Manipadam,Andrea Marra,Alan Ramsay et al.
Marie Therese Manipadam et al.
Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma [0.03%]
打破传统：惰性淋巴瘤单分次放射治疗的评估
Hazim S Ababneh,Chirayu G Patel
Hazim S Ababneh
As indolent non-Hodgkin's lymphomas (iNHLs) are very radiosensitive, radiation treatment (RT) has been established as an essential curative and palliative modality for early and advanced stages of the disease. Several studies have explored ...
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study [0.03%]
Polatuzumab Vedotin联合R-CHP方案治疗初治弥漫大B细胞淋巴瘤的疗效及安全性研究：一项真实世界多中心回顾性队列研究
Peiqi Zhao,Shu Zhao,Chen Huang et al.
Peiqi Zhao et al.
Polatuzumab vedotin plus R-CHP (Pola-R-CHP) is approved as a new standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) based on the POLARIX trial. However, real-world data on its efficacy and safety in unselected patients is...
Multicenter Study
Hematological oncology. 2025 Jan;43(1):e70017. DOI:10.1002/hon.70017 2025
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease [0.03%]
CPX-351与氟达拉滨为基础的诱导在继发性急性髓系白血病现实世界中的结局比较：可测量残留病预后的角色
Carola Riva,Paola Minetto,Maria Chies et al.
Carola Riva et al.
Secondary acute myeloid leukemia (s-AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG-Ida) have been tested to improve results. More recently, CPX-351 resulted superior to conventio...
Comparative Study
Hematological oncology. 2025 Jan;43(1):e70005. DOI:10.1002/hon.70005 2025
Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma [0.03%]
初诊即表现为低丙种球蛋白血症的弥漫性大B细胞淋巴瘤患者预后较差且感染风险更高
Åsa Lindberg,Åsa Johansson,Fredrik Kahn et al.
Åsa Lindberg et al.
There are some evidences that hypogammaglobulinemia in newly diagnosed diffuse large B cell lymphoma (DLBCL) is a predictor for inferior outcome, but the risk for infection-related admissions specifically related to hypogammaglobulinemia is...
Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT-Lymphoma) of the Intestine: A Single Center Analysis [0.03%]
黏膜相关淋巴组织结肠黏膜边缘区淋巴瘤的临床病理特征分析单中心报告
Oskar Steinbrecher,Barbara Kiesewetter,Werner Dolak et al.
Oskar Steinbrecher et al.
Extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) is an indolent B-cell lymphoma with a distinct affinity for mucosal structures. Most commonly arising in the stomach, only roughly 2% of MALT-...
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial [0.03%]
替尼司 mustard 在一组复发/难治性霍奇金淋巴瘤患者中的安全性和疗效：I 期临床试验的结果
Anna Sureda,Antonio Pinto,Hervé Ghesquières et al.
Anna Sureda et al.
A significant unmet need remains for patients with Hodgkin lymphoma (HL) who fail to respond to first-line treatment or experience an early relapse. Tinostamustine, a novel alkylating deacetylase inhibitor, inhibits tumor cell growth and sl...
Clinical Trial
Hematological oncology. 2025 Jan;43(1):e70000. DOI:10.1002/hon.70000 2025
Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma [0.03%]
18F-FDG PET/CT检查治疗前肿瘤负荷和弥散特征对进展期套细胞淋巴瘤预后的价值研究
Domenico Albano,Nicola Bianchetti,Anna Talin et al.
Domenico Albano et al.
Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with poor prognosis. The usefulness of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) and its parameters in the evaluation...
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance [0.03%]
与初始治疗耐药相关的弥漫性大B细胞淋巴瘤的分子特征
Allison M Bock,Kerstin Wenzl,Joseph P Novak et al.
Allison M Bock et al.
Diffuse large B-cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of the molecular drivers in DLBC...